| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?
|
Blood
|
2006
|
5.40
|
|
2
|
MicroRNA expression in cytogenetically normal acute myeloid leukemia.
|
N Engl J Med
|
2008
|
4.91
|
|
3
|
Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
|
J Clin Oncol
|
2008
|
4.09
|
|
4
|
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.
|
Blood
|
2007
|
3.41
|
|
5
|
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.
|
Blood
|
2011
|
3.32
|
|
6
|
High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.
|
J Clin Oncol
|
2007
|
3.04
|
|
7
|
Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
|
J Clin Oncol
|
2009
|
2.78
|
|
8
|
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.
|
Blood
|
2008
|
2.63
|
|
9
|
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.
|
Blood
|
2008
|
2.46
|
|
10
|
Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
|
Haematologica
|
2008
|
2.42
|
|
11
|
Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia.
|
Cancer Cell
|
2010
|
2.37
|
|
12
|
RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.
|
J Clin Oncol
|
2011
|
2.11
|
|
13
|
Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
|
Cancer
|
2005
|
1.82
|
|
14
|
Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.
|
J Clin Oncol
|
2011
|
1.79
|
|
15
|
Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study.
|
Blood
|
2006
|
1.74
|
|
16
|
Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.
|
Blood
|
2007
|
1.64
|
|
17
|
Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
|
J Clin Oncol
|
2009
|
1.63
|
|
18
|
Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method.
|
Nucleic Acids Res
|
2007
|
1.62
|
|
19
|
Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia.
|
Blood
|
2013
|
1.62
|
|
20
|
Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
J Clin Oncol
|
2010
|
1.59
|
|
21
|
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.
|
J Clin Oncol
|
2008
|
1.57
|
|
22
|
In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures.
|
Haematologica
|
2005
|
1.56
|
|
23
|
TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
|
J Clin Oncol
|
2012
|
1.36
|
|
24
|
Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).
|
Blood
|
2013
|
1.33
|
|
25
|
Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
|
Blood
|
2010
|
1.30
|
|
26
|
Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing.
|
Blood
|
2012
|
1.20
|
|
27
|
TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial.
|
Blood
|
2013
|
1.16
|
|
28
|
Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia.
|
Curr Opin Oncol
|
2008
|
1.14
|
|
29
|
The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA.
|
Blood
|
2013
|
1.11
|
|
30
|
High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations.
|
Blood
|
2012
|
1.09
|
|
31
|
NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG.
|
Blood
|
2013
|
1.09
|
|
32
|
Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
|
J Pharmacol Exp Ther
|
2007
|
1.06
|
|
33
|
The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemia.
|
Hematol Oncol
|
2010
|
0.95
|
|
34
|
An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR.
|
Haematologica
|
2007
|
0.87
|
|
35
|
SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.
|
J Clin Invest
|
2014
|
0.86
|
|
36
|
Normalization of previously shortened telomere length under treatment with imatinib argues against a preexisting telomere length deficit in normal hematopoietic stem cells from patients with chronic myeloid leukemia.
|
Ann N Y Acad Sci
|
2003
|
0.86
|
|
37
|
inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.
|
Blood
|
2012
|
0.84
|
|
38
|
Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia.
|
Blood
|
2003
|
0.83
|
|
39
|
Standardization of preanalytical factors for minimal residual disease analysis in chronic myelogenous leukemia.
|
Acta Haematol
|
2004
|
0.79
|